Madrigal Pharmaceuticals (MDGL) Upgraded by Zacks Investment Research to Hold

Madrigal Pharmaceuticals stock has undergone multiple analysts rating changes in the recent past.  Madrigal Pharmaceuticals Upgraded by Zacks Investment Research on 10/13/2021. In a note to investors, the firm issued a new rating of Hold. The analysts previously had rating of Sell.

Shares of Madrigal Pharmaceuticals traded up $0.86 on Tuesday, reaching $82.20. 0 shares of the stock traded hands, compared to its average volume of 107734. Shares of Madrigal Pharmaceuticals were trading at $82.20 on Tuesday. The firm’s 50 day moving average is $82.03 and its 200 day moving average is $105.92.Madrigal Pharmaceuticals has a 12 month low of $81.20 and a 12 month high of $142.62. While on yearly highs and lows, Madrigal Pharmaceuticals’s today has traded high as $84.60 and has touched $81.20 on the downward trend. See More Analyst Rating at: RATING

Madrigal Pharmaceuticals Earnings and What to expect: 

Madrigal Pharmaceuticals last posted its quarterly earnings results on August 5th, 2021. The biopharmaceutical company reported ($3.72) EPS for the quarter, missing the consensus estimate of ($3.58) by $0.14. Madrigal Pharmaceuticals has generated ($13.09) earnings per share over the last year (($14.61) diluted earnings per share). Earnings for Madrigal Pharmaceuticals are expected to grow in the coming year, from ($15.05) to ($14.39) per share. Madrigal Pharmaceuticals has not formally confirmed its next earnings publication date, but the company’s estimated earnings date is Thursday, November 4th, 2021 based off prior year’s report dates.

Earnings for Madrigal Pharmaceuticals are expected to grow in the coming year, from ($15.05) to ($14.39) per share. The P/E ratio of Madrigal Pharmaceuticals is -5.63, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings. The P/E ratio of Madrigal Pharmaceuticals is -5.63, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings. Madrigal Pharmaceuticals has a P/B Ratio of 5.30. P/B Ratios above 3 indicate that a company could be overvalued with respect to its assets and liabilities.

Madrigal Pharmaceuticals (MDGL) Moving Average Technical Analysis

5 day Moving Average is $80.71 And 5 day price change is $3.58 (4.55%)  with average volume for 5 day average is 101,500. While technical analysis for average 20 days shows significant difference, 20 day moving average is  $80.71 and 20 day price change is $3.02 (3.81%) and average 20 day moving volume is 111,750. 50 day moving average is $82.03  and 50 day price change is -$5.72 ( -6.51%)  and with average volume for 50 days is : 99,876. 200 day moving average is $105.92  and 200 day price change is -$37.92 (-31.57%)  and with average volume for 200 days is : 147,351.

Other owners latest trading in Madrigal Pharmaceuticals :

  • On 9/3/2021 shares held by Parametric Portfolio Associates LLC were 6,965 which equates to market value of $0.68M and appx 0.00% owners of Madrigal Pharmaceuticals
  • On 8/25/2021 shares held by Marshall Wace LLP were 98,180 which equates to market value of $9.56M and appx 0.00% owners of Madrigal Pharmaceuticals
  • On 8/25/2021 shares held by Marshall Wace North America L.P. were 95,380 which equates to market value of $9.29M and appx 0.00% owners of Madrigal Pharmaceuticals
  • In total Institutional ownership equates to Institutional Ownership Percentage: 69.32% for Madrigal Pharmaceuticals

See More Analyst Rating at: RATING